Search Results

Containing any of the words

Only of the type

SFDA Launches its new official electronic portal and announces its Twitter account News

CEO of SFDA Meets with Chinese Officials in Beijing to Enhance Cooperation News

Roundtable Connects SFDA with EU Officials and Business Leaders in Brussels News

The SFDA Held the First Consultation Meeting of Medical Devices Officials in the GCC News

Official launching of SFDA new portal Media Centre

"Study H9X-MC-GBGC is a Phase 3, randomized, double-blind, placebo-controlled trial withan open-label extension that investigates the effect of the addition of dulaglutide (0.75 and1.5 mg/week) or placebo weekly to metformin and/or basal insulin on change from baselinein hemoglobin A1c at 26 weeks in children and adolescents with type 2 diabetes mellitus" Drug Clinical Trial

"Study H9X-MC-GBGC is a Phase 3, randomized, double-blind, placebo-controlled trial with an open-label extension that investigates the effect of the addition of dulaglutide (0.75 and 1.5 mg/week) or placebo weekly to metformin and/or basal insulin on change from baseline in hemoglobin A1c at 26 weeks in children and adolescents with type 2 diabetes mellitus" Drug Clinical Trial

O-SEMA-Fast: A research study to understand how oral semaglutide works in people with type 2 diabetes who plan to fast during Ramadan in the United Arab Emirates, Saudi Arabia, and Kuwait Drug Clinical Trial

Saudi Food & Drug Authority Allows the Import and Use of AstraZeneca Covid19 Vaccine News

Randomized, two-way, two- period, single oral dose, open- label, crossover, bioequivalence study to compare Diclofenac Potassium powder for oral solution (50 mg diclofenac potassium) manufactured by Riyadh Pharma versus Catafast® powder for oral solution (50 mg diclofenac potassium) manufactured by Mipharm S.p.A., in healthy subjects under fasting condition. Drug Clinical Trial